Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States.
J Med Chem. 2021 Mar 11;64(5):2739-2761. doi: 10.1021/acs.jmedchem.0c02022. Epub 2021 Feb 23.
Malaria control programs continue to be threatened by drug resistance. To identify new antimalarials, we conducted a phenotypic screen and identified a novel tetrazole-based series that shows fast-kill kinetics and a relatively low propensity to develop high-level resistance. Preliminary structure-activity relationships were established including identification of a subseries of related amides with antiplasmodial activity. Assaying parasites with resistance to antimalarials led us to test whether the series had a similar mechanism of action to chloroquine (CQ). Treatment of synchronized parasites with active analogues revealed a pattern of intracellular inhibition of hemozoin (Hz) formation reminiscent of CQ's action. Drug selections yielded only modest resistance that was associated with amplification of the multidrug resistance gene 1 (). Thus, we have identified a novel chemical series that targets the historically druggable heme polymerization pathway and that can form the basis of future optimization efforts to develop a new malaria treatment.
疟疾控制项目继续受到抗药性的威胁。为了寻找新的抗疟药物,我们进行了表型筛选,发现了一种新型基于四唑的系列化合物,具有快速杀伤动力学和相对较低的产生高水平耐药性的倾向。初步的结构-活性关系已经建立,包括确定具有抗疟活性的相关酰胺的亚系列。用具有抗疟药物抗性的寄生虫进行检测,使我们能够测试该系列是否与氯喹(CQ)具有相似的作用机制。用活性类似物处理同步化寄生虫,发现其抑制血红素(Hz)形成的模式类似于 CQ 的作用。药物选择仅产生适度的耐药性,这与多药耐药基因 1()的扩增有关。因此,我们已经确定了一种新型化学系列,该系列针对历史上可用药的血红素聚合途径,并且可以作为未来开发新的疟疾治疗方法的优化工作的基础。